HY2233

HY2233 is an investigational small molecule muscle relaxant developed by Zhejiang Hengyan Pharmaceutical Technology Co., Ltd. for the treatment of skeletal muscle spasms. Classified as a Class 1 innovative drug in China, it is designed to reduce pathological muscle tension and alleviate spasticity. The drug has progressed through early-stage clinical evaluation, with Phase 1 trials conducted in healthy volunteers to assess its safety, tolerability, and pharmacokinetic profile following single and multiple oral doses. HY2233 aims to provide a therapeutic alternative to existing muscle relaxants with a potentially improved safety or efficacy profile.